ORBICULE

Serial Number 79388858
Registration 7510601
700

Registration Progress

Application Filed
Jul 4, 2023
Under Examination
Approved for Publication
Jul 9, 2024
Published for Opposition
Jul 9, 2024
Registered
Sep 24, 2024

Trademark Image

ORBICULE

Basic Information

Serial Number
79388858
Registration Number
7510601
Filing Date
July 4, 2023
Registration Date
September 24, 2024
Published for Opposition
July 9, 2024
Drawing Code
5

Status Summary

Current Status
Active
Status Code
700
Status Date
Sep 24, 2024
Registration
Registered
Classes
001 005 042

Rights Holder

ARGORNA PHARMACEUTICALS CO., LTD

99
Address
2nd and 4th Floor, Building A,
7 Suida Street, Huangpu District, Guangzhou Guangdong
CN

Ownership History

ARGORNA PHARMACEUTICALS CO., LTD

Original Applicant
99
CN

ARGORNA PHARMACEUTICALS CO., LTD

Owner at Publication
99
CN

ARGORNA PHARMACEUTICALS CO., LTD

Original Registrant
99
CN

Legal Representation

Attorney
Victoria Friedman

USPTO Deadlines

Next Deadline
1740 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20240924)
Due Date
September 24, 2030
Grace Period Ends
March 24, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

25 events
Date Code Type Description Documents
Jul 26, 2025 OPNX P NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Loading...
Jul 7, 2025 OPNS P NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Loading...
Jul 7, 2025 OPNR P NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Loading...
Mar 22, 2025 FINO P FINAL DECISION TRANSACTION PROCESSED BY IB Loading...
Mar 4, 2025 FICS P FINAL DISPOSITION NOTICE SENT TO IB Loading...
Mar 4, 2025 FIMP P FINAL DISPOSITION PROCESSED Loading...
Dec 24, 2024 FICR P FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Loading...
Sep 24, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Sep 24, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Jul 9, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jul 9, 2024 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jun 19, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jun 6, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jun 5, 2024 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jun 5, 2024 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jun 5, 2024 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Apr 24, 2024 RFNT P REFUSAL PROCESSED BY IB Loading...
Apr 2, 2024 RFCS P NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Loading...
Apr 2, 2024 RFRR P REFUSAL PROCESSED BY MPU Loading...
Mar 18, 2024 RFCR E NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Loading...
Mar 17, 2024 CNRT R NON-FINAL ACTION WRITTEN Loading...
Mar 16, 2024 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 16, 2024 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Feb 12, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Feb 9, 2024 REPR M SN ASSIGNED FOR SECT 66A APPL FROM IB Loading...

Detailed Classifications

Class 001
Test paper, chemical; chemical preparations in the nature of filtering materials for use in the manufacture of pharmaceuticals; chemical getters; acid proof chemical compositions for use in the manufacture of pharmaceuticals; antioxidants for use in the manufacture of pharmaceuticals; chemical reagents, other than for medical or veterinary purposes; chemical accelerants; chemical preparations for scientific purposes, other than for medical or veterinary use; biochemicals for scientific use; biochemical catalysts
Class 005
Pharmaceutical preparations for the treatment of tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; chemical preparations for medical purposes, namely, for the treatment of tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; antimicrobials for dermatologic use; nutritive substances for micro-organisms for medical use; sterilizing preparations; medicinal infusions for treating tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; reagent paper for medical purposes; diagnostic biomarker reagents for medical purposes; medicines for human purposes for treating tumors, asthma, arthritis, viral diseases, respiratory diseases, inflammation, fibrosis, hypertension, hyperlipidemia, cardiovascular diseases, eye diseases, angina, diabetes, and insomnia; chemical reagents for medical or veterinary purposes
Class 042
Chemical analysis; scientific laboratory services; chemical research; inspection of drugs for quality control purposes; biomedical research services; development of pharmaceutical preparations and pharmaceuticals; research and development services in the field of chemistry; pharmaceutical research

Additional Information

Design Mark
The mark consists of the stylized word "ORBICULE".

Classification

International Classes
001 005 042